Journal of Cardiac Failure最新文献

{"title":"Pocket lung ultrasound in ambulatory heart failure with preserved ejection fraction: pulmonary congestion as a point-of-care phenotype.","authors":"Sara Moura-Ferreira, Giulia Crisci, Jan Verwerft","doi":"10.1016/j.cardfail.2026.02.004","DOIUrl":"https://doi.org/10.1016/j.cardfail.2026.02.004","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When More (and Faster) is Better: Optimization of GDMT.","authors":"Laura P Cohen, James L Januzzi","doi":"10.1016/j.cardfail.2026.01.007","DOIUrl":"https://doi.org/10.1016/j.cardfail.2026.01.007","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variability in Status 1 Exception Practices and Candidate Outcomes After the 2018 U.S. Heart Allocation Changes.","authors":"Nikhil Narang, Thomas M Cascino, Jennifer A Cowger, Manreet K Kanwar, Maria Masotti, Rebecca Cogswell","doi":"10.1016/j.cardfail.2025.12.011","DOIUrl":"https://doi.org/10.1016/j.cardfail.2025.12.011","url":null,"abstract":"<p><strong>Background: </strong>Status 1 listings represents the highest priority for heart transplantation (HT) and is intended for candidates with the greatest medical urgency (i.e. VA-ECMO).</p><p><strong>Objectives: </strong>The study aims to assess the longitudinal changes in Status 1 listings, center-level listing variations, and implications on outcomes with or without an exception post-2018 allocation change.</p><p><strong>Methods: </strong>We analyzed de-identified OPTN data for adult first-time, single-organ HT candidates listed Status 1 between October 18, 2018-July 1, 2024 (n=2,123). Trends in overall and exception (1E) listings were evaluated by time, region, and center size. Fine-Gray sub distribution hazards regression were used to compare 30-day transplant and delisting for death/deterioration by exception status, and to identify characteristics associated with adverse outcomes.</p><p><strong>Results: </strong>Between 2018- 2024, Status 1 listings doubled from 7.1% to 14.4%, driven by a rise in 1E use (2.3% to 9.8%), which in 2024 comprised >50% of Status 1 listings. Use of exceptions varied widely by center and region. 1E candidates had similar 30-day transplant rates (sHR 0.97, 95% CI 0.88-1.07, P=0.5) but lower risk of delisting for death/deterioration compared with Status 1 candidates (sHR 0.69, 95% CI 0.48-0.98, P=0.041). In contrast, Status 1 candidates with blood group O or PRA ≥30% had lower rates of HT and higher rate of delisting for death/deterioration.</p><p><strong>Conclusion: </strong>Status 1 listings have increased substantially since 2018, driven by rising 1E use that varies widely across centers. Candidates listed with Status 1E appear less ill, while patients with disadvantages (blood group O and sensitization) remain at high risk for adverse outcomes.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146119023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving Indications, Challenges and Advances in Cardiac Resynchronization Therapy for Heart Failure","authors":"TEMIDAYO A. ABE MD ,&nbsp;ENDURANCE O. EVBAYEKHA MD ,&nbsp;LARRY R. JACKSON II MD, MHSc ,&nbsp;SANA M. AL-KHATIB MD, MHS ,&nbsp;SABRA C. LEWSEY MD, MPH ,&nbsp;KHADIJAH BREATHETT MD, MS","doi":"10.1016/j.cardfail.2025.01.031","DOIUrl":"10.1016/j.cardfail.2025.01.031","url":null,"abstract":"<div><div>Cardiac resynchronization therapy (CRT) via biventricular pacing has markedly improved heart failure outcomes over the past 2 decades. However, some patients show no clinical improvement or evidence of reverse remodeling following device implantation. Challenges include suboptimal patient selection, limitations in the characterization of conduction disease (especially nonspecific interventricular conduction delays), procedural constraints, inappropriate device programming, and delayed referral. Moreover, there remains no formal consensus on evaluating and characterizing CRT efficacy. Underuse persists among women and minoritized racial and ethnic groups. Targeted research addressing unmet needs has led to evolving guideline indications. Novel electrocardiographic and imaging techniques are continually being developed to improve patient selection, and alternative pacing strategies have emerged. Conduction system pacing may allow for a more physiological approach to CRT. Observational studies and small clinical trials have shown comparable or superior efficacy of conduction system pacing over traditional biventricular pacing; however, more studies are needed.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 2","pages":"Pages 499-514"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationale, design, and baseline characteristics of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 left ventricular assist device recipients (ENVAD-HF)","authors":"Maja Cikes MD, PhD ,&nbsp;Ivo Planinc MD, PhD ,&nbsp;Jasper J Brugts MD, PhD ,&nbsp;Brian Claggett PhD ,&nbsp;Ulrich P. Jorde MD ,&nbsp;Davor Milicic MD, PhD ,&nbsp;Frank Ruschitzka MD, PhD ,&nbsp;Nir Uriel MD, MSc ,&nbsp;Nina Jakus MD, PhD ,&nbsp;Filip Loncaric MD, PhD ,&nbsp;Filip Puskaric MD ,&nbsp;Pawel Rubis MD, PhD ,&nbsp;Linda W. van Laake MD, PhD ,&nbsp;Igor Rudez MD, PhD ,&nbsp;Marketa Hegarova MD, PhD ,&nbsp;Mandeep Mehra MD, MSc ,&nbsp;Scott D. Solomon MD","doi":"10.1016/j.cardfail.2025.07.015","DOIUrl":"10.1016/j.cardfail.2025.07.015","url":null,"abstract":"<div><h3>Background</h3><div>With notable improvements in long-term survival and hemocompatibility-related events, heart failure (HF) is emerging as a leading cause of death in the contemporary left ventricular assist device (LVAD) population. Although prospective randomized controlled trials have not investigated the use of HF therapies in recipients of LVAD, observational data suggest benefits of neurohormonal blockers, especially in achieving blood pressure (BP) targets associated with improved outcomes.</div></div><div><h3>Methods</h3><div>The study “multicENter, randomized, open-label, parallel group, pilot study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients” (ENVAD-HF) is an investigator-initiated prospective multicenter, randomized, open-label, parallel group, pilot study of recipients of HeartMate 3 (HM3) LVADs to evaluate the safety and tolerability and insights on efficacy of sacubitril/valsartan compared to standard of care (SOC) for managing BP. Medically stable recipients of LVADs after a recent HM3 implantation or in ambulatory follow-up were eligible for participation and randomized 1:1 to receive sacubitril/valsartan or SOC used for treating BP, both titrated aiming for a mean arterial pressure goal 75−90 mm Hg over a 12-month follow-up. The primary endpoint, designed to assess the safety and efficacy of sacubitril/valsartan compared with SOC, is a composite of freedom from all-cause death, deterioration in renal function, hyperkalemia, or symptomatic hypotension. The occurrence of the primary endpoint will be assessed in the first three months and during the overall duration of the trial (12 months). Other endpoints include clinical and patient-reported outcomes, biomarker, and echocardiography assessments during follow-up.</div></div><div><h3>Results</h3><div>ENVAD-HF enrolled 60 patients between February 2021 and March 2024: 17% were female, mean age was 57 ± 12 years, 67% were in ambulatory follow-up, 55% had ischemic etiology, and 25% were receiving an LVAD as destination therapy, with mean baseline mean arterial pressure 87 ± 7 mm Hg and median N-terminal pro B-type natriuretic peptide 2552 (1595−3543) pg/mL.</div></div><div><h3>Conclusion</h3><div>ENVAD-HF is the first prospective randomized controlled trial of pharmacologic therapy for the management of BP in stable recipients with HM3 LVADs achieving target enrollment. It will provide data on safety, tolerability, and insights on efficacy of sacubitril/valsartan versus SOC used for treating BP.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 2","pages":"Pages 406-418"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144862265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Mild and Moderate Aortic Stenosis in Acute Heart Failure: Insights From RELAX-AHF-2","authors":"CONSTANTIJN S. VENEMA MD ,&nbsp;MARCO METRA MD ,&nbsp;LAURA STAAL PhD ,&nbsp;IRIS E. BELDHUIS MD, PhD ,&nbsp;GAD COTTER MD ,&nbsp;BETH A. DAVISON PhD ,&nbsp;G. MICHAEL FELKER MD ,&nbsp;GERASIMOS FILIPPATOS MD, PhD ,&nbsp;BARRY H. GREENBERG MD ,&nbsp;PETER S. PANG MD ,&nbsp;PIOTR PONIKOWSKI MD ,&nbsp;CLAUDIO GIMPELEWICZ MD ,&nbsp;ERIK LIPSIC MD, PhD ,&nbsp;ADRIAAN A. VOORS MD, PhD ,&nbsp;JOHN R. TEERLINK MD ,&nbsp;JOANNA J. WYKRZYKOWSKA MD, PhD","doi":"10.1016/j.cardfail.2025.07.017","DOIUrl":"10.1016/j.cardfail.2025.07.017","url":null,"abstract":"<div><h3>Background</h3><div>Aortic stenosis leads to increased afterload, which may be detrimental in a failing left ventricle and has been associated with an increased risk of hospitalizations due to heart failure and mortality in chronic heart failure. The prevalence and impact of aortic stenosis in acute heart failure are less well described. This post hoc analysis aimed to evaluate the prevalence and prognostic impact of aortic stenosis in a large cohort of patients hospitalized due to acute heart failure.</div></div><div><h3>Methods and Results</h3><div>All patients from the Relaxin in Acute Heart Failure 2 (RELAX-AHF-2) trial with data available on aortic stenosis severity were included in the present analysis (n = 6241). Patients with severe aortic stenosis were ineligible for RELAX-AHF-2. Baseline characteristics, in-hospital outcomes and 180-day clinical outcomes were compared between patients with and without aortic stenosis. Mild or moderate aortic stenosis was present in 454 (7.3%) patients. Patients with aortic stenosis were older, more commonly female, had more comorbidities, and had higher left ventricular ejection fractions compared to patients without aortic stenosis. Mild or moderate aortic stenosis was associated with a higher risk of cardiovascular mortality or readmission for heart or renal failure (unadjusted hazard ratio (HR) 1.32, 95% CI 1.11–1.57). This association was maintained when adjusting for age and sex, but not after comprehensive multivariable adjustment (adjusted HR 1.04, 95% CI 0.82–1.32).</div></div><div><h3>Conclusion</h3><div>The presence of mild or moderate aortic stenosis reflects an increased risk profile in patients with acute heart failure, but it is not an independent predictor of poor clinical outcomes.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 2","pages":"Pages 419-429"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Heart Failure Cardiogenic Shock Patients with Axillary and Femoral Intra-aortic Balloon Pump: Cardiogenic Shock Working Group report","authors":"ARVIND BHIMARAJ MD, MPH ,&nbsp;ARTHUR R. GARAN MD ,&nbsp;QIUYUE KONG ,&nbsp;JU KIM MD ,&nbsp;MOHIT PAHUJA MD ,&nbsp;AJAR KOCHAR MD ,&nbsp;SMITHA NARAYANGOWDA ,&nbsp;BORUI LI ,&nbsp;SONG LI MD ,&nbsp;SHASHANK S. SINHA MD, MSc ,&nbsp;GAVIN W. HICKEY MD ,&nbsp;RACHNA KATARIA MD ,&nbsp;VAN-KHUE TON MD, PhD ,&nbsp;SCOTT LUNDGREN MD ,&nbsp;SANDEEP NATHAN MD ,&nbsp;ESTHER VOROVICH MD ,&nbsp;SHELLEY HALL MD ,&nbsp;WISSAM KHALIFE MD ,&nbsp;ANDREW SCHWARTZMAN MD ,&nbsp;OLEG ALEC VISHNEVSKY MD ,&nbsp;NAVIN K. KAPUR MD","doi":"10.1016/j.cardfail.2025.07.020","DOIUrl":"10.1016/j.cardfail.2025.07.020","url":null,"abstract":"<div><h3>Background</h3><div>IABPs traditionally are placed via the femoral artery. Single-center studies have shown the utility of axillary placement to promote ambulation. The utility of Ax IABP in CS has not been established. Therefore, we sought to describe the outcomes of patients receiving axillary (Ax) intra-aortic balloon pump (IABP) and compare them with those receiving femoral (Fem) IABP for heart failure-related cardiogenic shock (HF-CS).</div></div><div><h3>Methods</h3><div>Data from 2020 to 2023 from the Cardiogenic Shock Working Group, a multicenter academic consortium, were analyzed. We examined the demographic, metabolic, hemodynamic characteristics, and outcomes of patients with HF-CS treated with Ax-IABP and compared them with those who primarily received a Fem-IABP.</div></div><div><h3>Results</h3><div>Of 6201 CS patients in the registry, 557 (8.9%) patients received an IABP for HF-CS, of whom 244 (43.8%) and 313 (56.2%) received Ax-IABP and Fem-IABP, respectively. Compared with Fem-IABP, patients who received Ax-IABP were more likely to have previous intracardiac defibrillators (42.5% vs 68.9%, <em>P</em> &lt; .001). Time to IABP implant from admission (7.9 ± 10.6 vs 1.8 ± 6.1, <em>P</em> &lt; .01) and duration of support (9.6 ± 14.6 vs 4.0 ± 4.5, <em>P</em> &lt; .01) were longer among Ax-IABP, relative to Fem-IABP. Patients who received Ax-IABP were more likely to undergo heart-replacement therapy (65% vs 21%, <em>P</em> &lt; .001) compared with the Fem-IABP cohort. The rate of reported complications was similar between the 2 groups.</div></div><div><h3>Conclusion</h3><div>Axillary IABP is being used beyond single-center reports to support HF-CS mostly as a bridge to heart-replacement therapies. Its use might provide advantages over fem-IABP.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 2","pages":"Pages 394-405"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes Among Pregnant Women With Hypertrophic Cardiomyopathy: Racial and Ethnic Differences in the United States","authors":"DUKE APPIAH Ph.D., M.Ph., M.S. ,&nbsp;OLUWATOBI E. OLADEJI M.D., M.Ph. ,&nbsp;ERIC K. BRONI M.D., M.Ph. ,&nbsp;IMO A. EBONG M.D., M.S. ,&nbsp;CATHERINE KIM M.D.","doi":"10.1016/j.cardfail.2025.07.012","DOIUrl":"10.1016/j.cardfail.2025.07.012","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 2","pages":"Pages 538-540"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary Waitlist and Post–Heart Transplant Outcomes for Fontan patients: An International Multi-Institutional Analysis","authors":"SHAHNAWAZ AMDANI MD, FAHA, FACC, FAAP ,&nbsp;EDO BEDZRA MD ,&nbsp;DEVIN KOEHL MS ,&nbsp;RYAN CANTOR PhD ,&nbsp;JAMES K. KIRKLIN MD ,&nbsp;RYAN L. KOBAYASHI MD ,&nbsp;NATALIE SHWAISH MD ,&nbsp;ADAM PUTSCHOEGL MD ,&nbsp;STEVEN D. ZANGWILL MD ,&nbsp;NEHA BANSAL MD ,&nbsp;NANCY J. HALNON MD","doi":"10.1016/j.cardfail.2025.08.028","DOIUrl":"10.1016/j.cardfail.2025.08.028","url":null,"abstract":"<div><h3>Background</h3><div>Pediatric patients with Fontan circulation represent a growing, high-risk cohort of heart transplant (HT) candidates. However, contemporary multi-institutional data on their waitlist and post-transplant outcomes are limited.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of children aged 2 to &lt;18 years listed for HT in the Pediatric Heart Transplant Society database from 1993 to 2023. Patients were categorized as having Fontan circulation, non-Fontan congenital heart disease (CHD), or cardiomyopathy (CMP). Outcomes were analyzed across early (1993–2014) and current (2015–2023) eras. Cox proportional hazards models identified risk factors for waitlist mortality and post-transplant graft loss.</div></div><div><h3>Results</h3><div>Among 6061 listed patients, 22.3% had Fontan circulation, 24.1% non-Fontan CHD, and 53.6% CMP. In the current era, 54.6% of CHD listings are Fontan patients. Fontan patients were significantly less likely to receive ventricular assist device (VAD) support at listing (2.6%) or transplant (4.7%) compared to CMP (16.4%, 29.5%; <em>P</em> &lt; .001). Waitlist survival has improved significantly, with no differences among diagnostic groups in the current era (<em>P</em> = .109). However, Fontan patients had a 2-fold higher risk of post-transplant graft loss compared to CMP (HR 1.99, <em>P</em> &lt; .0001) and experienced higher rates of post-transplant infection and malignancy (<em>P</em> &lt; .05). Among Fontan patients, VAD-supported individuals had similar post-transplant survival to those without mechanical support and significantly better survival than those supported with extracorporeal membrane oxygenation (<em>P</em> &lt; .0001).</div></div><div><h3>Conclusions</h3><div>Fontan patients now represent the largest CHD subgroup listed for HT. While waitlist outcomes have improved, posttransplant outcomes remain inferior. Selective and timely use of VAD support may improve survival in this high-risk population.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 2","pages":"Pages 430-438"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145504134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pumping up Survival: Strategy of LVAD First in Younger Patients for Net Prolongation of Life","authors":"RANDALL C. STARLING MD, MPH, FACC, FAHA, FESC, FHFSA,&nbsp;MICHAEL Z. TONG MD, MBA,&nbsp;EDWARD G. SOLTESZ MD, MPH","doi":"10.1016/j.cardfail.2025.10.011","DOIUrl":"10.1016/j.cardfail.2025.10.011","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"32 2","pages":"Pages 541-543"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145458804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}